Universitätsklinikum Frankfurt in Germany was the first study site to be activated for the RSV vaccine effectiveness study in adults […]
Category: Newsroom
Second in-person Site Investigator meeting
On 28 April 2024, the second in-person Study Contributor (Site) Investigator meeting took place as a satellite meeting during the […]
Poster presentation during ESCMID Global 2024
During the 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) held in Barcelona, Spain on […]
id.DRIVE welcomes 3 new members to its Independent Scientific Committee
With id.DRIVE´s expansion of scope beyond COVID-19 and broadened studies’ portfolio, we recently extended the breadth of expertise and number […]
id.DRIVE has activated a new Study Contributor (study site) in Italy
id.DRIVE has activated Luigi Sacco Hospital on February 28th, 2024. Luigi Sacco Hospital is located in north Milan, Italy, and […]
COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases.
id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who […]
Site Investigators’ meeting
COVIDRIVE´s second virtual site investigators meeting took place on December 14th, 2023. We welcomed participants from sites in Spain, Italy, […]
Second annual face-to-face COVIDRIVE Steering Committee meeting
On November 28th and 29th, 2023, the members of the COVIDRIVE Steering Committee met in Valencia, Spain to discuss the […]
COVIDRIVE has reached a milestone: enrolment of over 10,000 patients
We are pleased to announce that the first COVIDRIVE study has recruited 10,038 patients across 17 hospitals in 5 European countries. This high recruitment number is important […]
AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe.
The study concluded that primary-series vaccination with AstraZeneca´s COVID-19 vaccine confers protection against COVID-19 hospitalisation with enduring levels of vaccine […]